You are here: Industry Insights > cGMP

News List

Sparx Therapeutics to build first commercial antibody drug production facility in China cphi-online
July 15, 2021
The emerging biotech company unveils plans for a 1.2 million-sq. ft manufacturing facility in Yangzhou
Recro Pharma Inks Development and Mfg. Pact contractpharma
July 14, 2021
To support a client’s ongoing clinical development of an orally administered, minimally-absorbed investigational compound.
LGM Pharma launches analytical and stability testing as standalone service cphi-online
July 13, 2021
LGM Pharma, a company offering integrated CDMO services, is launching its analytical services and facilities as a standalone contract service for drug developers and manufacturers.
LGM Pharma Launches Analytical Services for Drug Developers and Manufacturers contractpharma
July 09, 2021
LGM Pharma has launched its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies.
Genezen Breaks Ground on cGMP Lentiviral Vector Production Facility contractpharma
June 28, 2021
First phase will see the construction of a 25,000 square feet site including a process development lab expansion.
Genezen begins construction of cGMP lentiviral production facility cphi-online
June 28, 2021
Genezen has made a start on turning its new multiphase master plan for a 75,000-sq. ft cGMP-compliant lentiviral vector production facility into reality.
DuPont Expands Ion Exchange Production to Meet Pharmaceutical Demand americanpharmaceuticalreview
June 25, 2021
DuPont Water Solutions is a producer of separation and filtration technologies, including reverse osmosis and ultrafiltration membranes, as well as ion exchange resins.
Dendreon Pharmaceuticals Establishes Contract Manufacturing Division contractpharma
June 16, 2021
Now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs.
Vibalogics Expands Manufacturing Capacity contractpharma
June 15, 2021
Vibalogics, a global contract development and manufacturing organization (CDMO), initiated the first stage of a $50 million investment at its Cuxhaven, Germany facility, expanding early-to-late phase clinical virotherapy manufacturing capacity.
Vibalogics invests an additional $50 million to further expand cGMP manufacturing capacity for viral vectors firstwordpharma
June 10, 2021
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated the first stage of a planned $50 million dollar investment at its Cuxhaven, Germany facility, expanding early-to-late phase clinical

Previous page 1 2 3 4 5 6 7 8 9 Next page